IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options for an aggregate 98,000 common shares to four newly hired employees on June 25, 2026. The awards were made under the 2023 Employment Inducement Incentive Award Plan in line with Nasdaq Listing Rule 5635(c)(4).

The options have a $36.29 exercise price, a 10-year term, and vest over four years: 25% after one year and the remaining 75% in equal monthly installments over three years, subject to continued service.

Positive

• Inducement grants of 98,000 options to attract and retain new talent
• Exercise price set at $36.29, aligned with grant-date market closing price

Negative

• New stock options for 98,000 shares introduce potential future equity dilution

News Market Reaction – IDYA

+1.24%

+1.24% Session close to close

In the Jun 26 session, IDYA gained 1.24%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement stock options for four new hires totaling 98,000 shares at $36....

Analysis

This announcement details inducement stock options for four new hires totaling 98,000 shares at $36.29 with a 10-year term and four-year vesting. Routine equity compensation follows recent offerings; investors may watch how ongoing grants and shelf usage affect future dilution.

Key Figures

Inducement options granted: 98,000 shares Employees receiving grants: 4 employees Exercise price: $36.29 per share +5 more

8 metrics

Inducement options granted 98,000 shares Non-qualified stock options to four newly hired employees

Employees receiving grants 4 employees New hires receiving inducement stock option awards

Exercise price $36.29 per share Equal to IDYA Nasdaq closing price on June 25, 2026

Option term 10 years Contractual term of the inducement stock options

Vesting period 4 years Standard vesting schedule for inducement stock options

Initial vesting tranche 25% of options Vests on first anniversary of vesting commencement date

Remaining vesting 75% of options Vests in equal monthly installments over following three years

Pre-news price $36.29 per share Last price before announcement; near 52-week high of $39.28

Historical Context

5 past events · Latest: Jun 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 17	Leadership change	Positive	+2.3%	CEO Yujiro S. Hata elected Chairman, reinforcing leadership continuity and oversight.
Jun 15	Clinical trial start	Positive	+4.3%	Phase 1/2 combo study for IDE892 in MTAP-deleted cancers initiated and enrolling.
Jun 10	Equity offering close	Neutral	+4.5%	Closing of underwritten equity and warrant offering with substantial gross proceeds raised.
Jun 08	Offering priced	Negative	-7.6%	Pricing of large common stock and pre-funded warrant offering signaling equity dilution.
Jun 08	Offering proposed	Negative	-7.6%	Announcement of proposed $300M equity and pre-funded warrant offering under shelf.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

IDYA often reacts by several percent to financings and clinical updates, with price moves generally aligning with the tone of prior announcements.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, exercise price, vesting commencement date, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 98,000 shares of the Company's common stock"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"The stock options have an exercise price of $36.29 per share, which is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting commencement date financial

"25% of the options vesting on the first anniversary of the vesting commencement date and the remaining"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

inducement plan financial

"2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., June 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 25, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 98,000 shares of the Company's common stock to four newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $36.29 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302811536.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What stock options did IDEAYA Biosciences (NASDAQ: IDYA) grant on June 25, 2026?

IDEAYA Biosciences granted non-qualified stock options to purchase 98,000 common shares to four newly hired employees. According to IDEAYA, these inducement awards were approved by the Compensation Committee as part of the company’s 2023 Employment Inducement Incentive Award Plan.

What is the exercise price and term of the new IDEAYA (IDYA) employee stock options?

The newly granted IDEAYA stock options have a $36.29 exercise price and a 10-year term. According to IDEAYA, the exercise price equals the June 25, 2026 Nasdaq Global Select Market closing price of the company’s common stock on the grant date.

How do the IDEAYA (IDYA) inducement stock options vest for new employees?

The IDEAYA inducement stock options vest over four years, subject to continued service. According to IDEAYA, 25% of the options vest on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the following three years.

Under which plan and Nasdaq rule were IDEAYA (IDYA) inducement options granted?

The options were granted under IDEAYA’s 2023 Employment Inducement Incentive Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4). According to IDEAYA, this plan is used exclusively for equity awards to new hires as a material inducement to employment.

Who is eligible for IDEAYA Biosciences 2023 Inducement Plan equity awards?

IDEAYA’s 2023 Inducement Plan is limited to individuals not previously employed by the company, or rehires after a bona fide break. According to IDEAYA, awards are granted as a material inducement for these individuals to enter into employment with the company.

What does the IDEAYA (IDYA) inducement grant mean for existing shareholders?

The inducement grant authorizes options for 98,000 shares, which may create future dilution if exercised. According to IDEAYA, the awards are targeted to new employees and are intended to support recruitment and long-term alignment through equity-based compensation.